17β-estradiol attenuates homocysteine-induced oxidative stress and inflammatory response as well as MAPKs cascade via activating PI3-K/Akt signal transduction pathway in Raw 264.7 cells

Acta Biochimica et Biophysica Sinica

Volumn 47, Issue 2, 2015, Pages 65-72

  Zhang, Ying ^a   He, Ying ^a   Zong, Yi ^a   Guo, Jiazhi ^a   Sun, Lin ^a   Ma, Yunbing ^b   Dong, Wei ^c   Gui, Li ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b The Third People's Hospital of Yunnan Province   (China)

^c YUNNAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

17 estradiol; homocysteine; MAPKs; PI3 K Akt; reactive oxygen species

Indexed keywords

MURINAE;

ESTRADIOL; HOMOCYSTEINE; INTERLEUKIN 1BETA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; CELL LINE RAW 264.7; CELL SURVIVAL; INFLAMMATION; METABOLISM; MOUSE; OSTEOPOROSIS; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

ANIMALS; CELL SURVIVAL; ESTRADIOL; HOMOCYSTEINE; INFLAMMATION; INTERLEUKIN-1BETA; MAP KINASE SIGNALING SYSTEM; MICE; OSTEOPOROSIS; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; RAW 264.7 CELLS; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925146608     PISSN: 16729145     EISSN: 17457270     Source Type: Journal    
DOI: 10.1093/abbs/gmu124     Document Type: Article

References (54)

1. Looker AC, Orwoll ES, Johnston CC Jr, Lindsay RL, Wahner HW, Dunn WL, Calvo MS, et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997, 12: 1761-1768
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteston A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007, 22: 465-475
3. Hernlund E, Svedbom A, Ivergå;rd M, Compston J, Cooper C, Stenmark J, McCloskey EV, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013, 8: 136
4. Yang J, Hu X, Zhang Q, Cao H, Wang J, Liu B. Homocysteine level and risk of fracture: a meta-Analysis and systematic review. Bone 2012, 51: 376-382
5. Kuroda T, Tanaka S, Saito M, Shiraki Y, Shiraki M. Plasma level of homocysteine associated with severe vertebral fracture in postmenopausal women. Calcif Tissue Int 2013, 93: 269-275
6. Yilmaz N, Eren E. Homocysteine oxidative stress and relation to bone mineral density in post-menopausal osteoporosis. Aging Clin Exp Res 2009, 21: 353-357
7. Lee SH, Kim MJ, Kim BJ, Kim SR, Chun S, Ryu JS, Kim GS, et al. Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease. Mov Disord 2010, 25: 332-340
8. Kyriakis JM, Avruch J. Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012, 92: 689-737
9. Lee YS, Lee SJ, Seo KW, Bae JU, Park SY, Kim CD. Homocysteine induces COX-2 expression in macrophages through ROS generated by NMDA receptor-calcium signaling pathways. Free Radic Res 2013, 47: 422-431
10. Manolagas SC. From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocr Rev 2010, 31: 266-300
11. Yin H, Shi ZG, Yu YS, Hu J, Wang R, Luan ZP, Guo DH. Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats. Eur J Pharmacol 2012, 674: 200-206
12. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005, 328: 688-696
13. Miyauchi Y, Sato Y, Kobayashi T, Yoshida S, Mori T, Kanagawa H, Katsuyama E, et al. HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci USA 2013, 41: 16568-16573
14. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003, 290: 1729-1738
15. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. J Clin Endocrinol Metab 2002, 87: 4914-4923
16. Zong Y, Sun L, Liu B, Deng YS, Zhan D, Chen YL, He Y, et al. Resveratrol inhibits LPS-induced MAPKs activation via activation of the phosphatidylinositol 3-kinase pathway in murine Raw 264.7 macrophage cells. PLoS One 2012, 7: e44107
17. Feng D, Zhou Y, Xia M, Ma J. Folic acid inhibits lipopolysaccharideinduced inflammatory response in RAW264.7 macrophages by suppressing MAPKs and NF-?B activation. Inflamm Res 2011, 60: 817-822
18. Hou GQ, Guo C, Song GH, Fang N, Fan WJ, Chen XD, Yuan L, et al. Lipopolysaccharide (LPS) promotes osteoclast differentiation and activation by enhancing the MAPK pathway and COX-2 expression in RAW264.7 cells. Int J Mol Med 2013, 32: 503-510
19. Li DZ, Zhag QX, Dong XX, Li HD, Ma X. Treatment with hydrogen molecules prevents RANKL-induced osteoclast differentiation associated with inhibition of ROS formation and inactivation of MAPK, AKT and NF-kappa B pathways in murine RAW264.7 cells. J Bone Miner Metab 2014, 32: 494-504
20. Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, Andria G, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985, 37: 1-31
21. Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999, 19: 217-246
22. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Väänänen HK, Obrant KJ, AkessonK.Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J BoneMiner Res 2007, 22: 127-134
23. Leboff MS, Narweker R, LaCroix A, Wu L, Jackson R, Lee J, Bauer DC, et al. Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab 2009, 94: 1207-1213
24. Claes L, Schmalenbach J, Herrmann M, Olkü I, Garcia P, Histing T, Obeid R, et al. Hyperhomocysteinemia is associated with impaired fracture healing in mice. Calcif Tissue Int 2009, 85: 17-21
25. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, Lee KU, et al. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 2006, 21: 1003-1011
26. Herrmann M, Tami A, Wildemann B, Wolny M, Wagner A, Schorr H, Taban-Shomal O, et al. Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone 2009, 44: 467-475
27. Thaler R, Agsten M, Spitzer S, Paschalis EP, Karlic H, Klaushofer K, Varga F. Homocysteine suppresses the expression of the collagen crosslinker lysyl oxidase involving IL-6, Fli1, and epigenetic DNA methylation. J Biol Chem 2011, 286: 5578-5588
28. Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A. Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 2003, 6: 956-959
29. El Maghraoui A, Ghozlani I, Mounach A, Rezqi A, Oumghar K, Achemlal L, Bezza A, et al. Homocysteine, folate, and vitamin B12 levels and vertebral fracture risk in postmenopausalwomen. J ClinDensitom2012, 15: 328-333
30. White J, Morton V, Whittington K, Wilson G, Tucci M, Benghuzzi H. The effects of dematerialized bone matrix proteins, estrogen, and an antagonist to neuropeptide y on osteoblast and osteoclast viability and function related to osteoporosis. Biomed Sci Instrum 2012, 48: 478-484
31. Clowes JA, Eghbali-Fatourechi GZ, McCready L, Oursler MJ, Khosla S, Riggs BL. Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. Osteoporos Int 2009, 20: 761-769
32. Luo CY, Wang L, Sun C, Li DJ. Estrogen enhances the functions of CD4(+) CD25(+)Foxp3(+) regulatory T cells that suppress osteoclast differentiation and bone resorption in vitro. Cell Mol Immunol 2011, 8: 50-58
33. Silverman SL, Christiansen C, Genant HK, Vukicevic S, Zanchetta JR, de Villiers TJ, Constantine GD, et al. Efficacy of baze-doxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008, 23: 1923-1934
34. Silverman SL, Chines AA, Kendler DL, Kung AW, Teglbjærg CS, Felsenberg D, Mairon N. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmeno-pausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012, 23: 351-363
35. Vijayan V, Khandelwal M, Manglani K, Singh RR, Gupta S, Surolia A. Homocysteine alters the osteoprotegerin/RANKL system in the osteoblast to promote bone loss: pivotal role of the redox regulator forkhead O1. Free Radic Biol Med 2013, 61: 72-84
36. Katso R, Okkenhaug K, Ahmadi K, White S, Waterfield MD. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001, 17: 615-675
37. Kinjo M, Minami A, Iwasaki N. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/AKT and Erk pathways in association with signaling adaptor DAP12. J Bone Miner Res 2013, 28: 2463-2475
38. Moon JB, Kim JH, Kim K, Youn BU, Ko A, Lee SY, Kim N. AKT induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J Immunol 2012, 188: 163-169
39. Cicek M, Vrabel A, Sturchio C, Pederson L, Hawse JR, Subramaniam M, Spelsberg TC, et al. TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways. PLoS One 2011, 6: e17522
40. Xiao-Hong D, Chang-Qin X, Jian-Hua H, Wen-Jiang Z, Bing S. Icariin delays homocysteine-induced endothelial cellular senescence involving activation of the PI3K/AKT-eNOS signaling pathway. Pharm Biol 2013, 51: 433-440
41. Lee SJ, Lee YS, Seo KW, Bae JU, Kim GH, Park SY, Kim CD. Homocysteine enhances MMP-9 production in murine macrophages via ERK and AKT signaling pathways. Toxicol Appl Pharmacol 2012, 260: 89-94
42. Yan TT, Li Q, Zhang XH, Wu WK, Sun J, Li L, Zhang Q, et al. Homocysteine impaired endothelial function through compromised vascular endothelial growth factor/AKT/endothelial nitric oxide synthase signaling. Clin Exp Pharmacol Physiol 2010, 37: 1071-1077
43. Li XQ, Cao W, Li T, Zeng AG, Hao LL, Zhang XN, Mei QB. Amlodipine inhibits TNF-Alpha production and attenuates cardiac dysfunction induced by lipopolysac-charide involving PI3K/AKT pathway. Int Immunopharmacol 2009, 9: 1032-1041
44. Shastry S, James LR. Homocysteine-induced macrophage inflammatory protein-2 production by glomerular mesangial cells is mediated by PI3 Kinase and p38 MAPK. J Inflamm (Lond) 2009, 6: 27
45. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-Activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22: 153-183
46. Chaves de Souza JA, Nogueira AV, Chaves de Souza PP, Kim YJ, Silva Lobo C, Pimentel Lopes de OGJ, Cirelli JA, et al. SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation in vivo. Mediators Inflamm 2013, 2013: 650812
47. Lin MC, Pan CY, Hui CF, Chen JY, Wu JL. Shrimp anti-lipopolysaccharide factor (SALF), an antimicrobial peptide, inhibits proinflammatory cytokine expressions through the MAPK and NF-?B pathways in LPS-induced HeLa cells. Peptides 2013, 40: 42-48
48. Dai JN, Zong Y, Zhong LM, Li YM, Zhang W, Bian LG, Ai QL, et al. Gastrodin inhibits expression of inducible NO synthase, cyclooxygenase-2 and proinflammatory cytokines in cultured LPS-stimulated microglia via MAPK pathways. PLoS One 2011, 6: e21891
49. Weitzmann MN. The role of inflammatory cytokines, the RANKL/OPG Axis, and the immunoskeletal interface in physiological bone turnover and osteoporosis. Scientifica (Cairo) 2013, 2013: 125705
50. Lee BJ, Huang YC, Chen SJ, Lin PT. Effects of coenzyme Q10 supplementation on inflammatory markers (high-sensitivity C-reactive protein, interleukin-6, and homocysteine) in patients with coronary artery disease. Nutrition 2012, 28: 767-772
51. Wang D, Wang H, Luo P, Hwang A, Sun D, Wang Y, Zhang Z, et al. Effectsof ghrelin on homocysteine-induced dysfunction and inflammatory response in rat cardiac microvascular endothelial cells. Cell Biol Int 2012, 36: 511-517
52. da Cunha AA, Ferreira AG, Wyse AT. Increased inflammatory markers in brain and blood of rats subjected to acute homocysteine administration. Metab Brain Dis 2010, 25: 199-206
53. Aksamitiene E, Kiyatkin A, Kholodenko BN. Cross-Talk between mitogenicRas/MAPK and survival PI3K/AKT pathways: a fine balance. Biochem Soc Trans 2012, 40: 139-146
54. Dent P. Crosstalk between ERK, AKT, and cell survival. Cancer Biol Ther 2014, 15: 245-246